REVERA has published its annual pharmaceutical market regulation review!
26 March 2019
The review offers: - 33 pages of up-to-date information about Belarusian pharmaceutical legislation prepared by REVERA lawyers; - answers to all questions crucial for pharmaceutical companies: from state registration of pharmaceuticals to advertising issues in Belarus; - examples and graphic explanations for better information sensing.
This review aims at helping foreign pharmaceutical companies in making their informed decisions on the opportunities and risks of doing business in Belarus.
Pharmaceutical markets around the globe are subject to variuos peculiarities of regulatory norms, and Belarus is no exception. Many pharmaceutical reviews in various countries would either contain only most superficial information, or, on the contrary, offer almost entire contents of applicable legislation. Our review aims at more than depicting a specific regulation pattern applied to the Belarusian pharmaceutical market. Our review’s goal is to help you to independently assess risks and form a competent and impartial judgement about the business opportunities in Belarus. This review offers a comprehensive presentation of norms that regulate our country’s pharmaceutical market.
We believe that this review will be most useful for companies that treat Belarus as their prospective market, either for the production or for the sales of medical goods. This review contains characteristics of regulations applied to all pharmaceutical business spheres, from registration and imports to price formation.